ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition
"We believe the new data being reported with our IMGN529 and IMGN779
ADCs will help convey why we believe these have the potential to make
important differences for patients with certain B-cell malignancies and
acute myeloid leukemia, respectively," commented
Presentations on ImmunoGen Wholly Owned ADCs
Title: "A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)."
-
Poster session (PS) #624:
Saturday, Dec. 6 ,5:30-7:30 pm PST . Abstract #1760.
Title: "Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)."
-
PS #625:
Sunday, Dec. 7 ,6:00-8:00 pm PST . Abstract #3119.
Title: "The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations."
-
PS #616:
Sunday, Dec. 7 ,6:00-8:00 pm PST . Abstract #2321.
Presentations on Partner Compounds
Title: "
-
PS #653:
Saturday, Dec. 6 ,5:30-7:30 pm PST . Abstract #2124.
Title: "KIR and HLA Genotypes Influence Clinical Outcome in Multiple
Myeloma Patients Treated with
-
PS #653:
Saturday, Dec. 6 ,5:30-7:30 pm PST . Abstract #2126.
Title: "A Phase Ib Dose Escalation Trial of
-
Presentation time:
Sunday, Dec. 7 , at1:00 pm PST . Abstract #83.
Title: "Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib."
-
PS #653:
Monday, Dec. 8 ,6:00-8:00 pm PST . Abstract #4736.
Additional information can be found at www.hematology.org, including the abstracts.
About
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including IMGN529, IMGN779, BT-062, and
For Investors:
info@immunogen.com
or
For
Media:
Source:
News Provided by Acquire Media